Progress and obstacles in the development of an AIDS vaccine.
about
The use of nonhuman primate models in HIV vaccine developmentThe failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT miceHLA-driven convergence of HIV-1 viral subtypes B and F toward the adaptation to immune responses in human populationsA vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II moleculesEfficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialHIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentHIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility.The cat and mouse of HIV-1 antibody escape.A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strainsA cluster randomized controlled trial of an adolescent HIV prevention program among Bahamian youth: effect at 12 months post-intervention.Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys.Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.A critical role for virus-specific CD8(+) CTLs in protection from Theiler's virus-induced demyelination in disease-susceptible SJL mice.Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.A novel immunodominant CD8+ T cell response restricted by a common HLA-C allele targets a conserved region of Gag HIV-1 clade CRF01_AE infected ThaisAvailability of HIV postexposure prophylaxis services in Los Angeles CountyMagnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccineVariable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.Very few substitutions in a germ line antibody are required to initiate significant domain exchange.Challenges in the design of a T cell vaccine in the context of HIV-1 diversity.Critical issues in mucosal immunity for HIV-1 vaccine development.Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis.CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individualsPriming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice.Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.Human immunodeficiency virus vaccinesComparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein BoostA clinic-based motivational intervention improves condom use among subgroups of youth living with HIVNanotechnology Applications to HIV Vaccines and Microbicides.Fruit-specific expression of the human immunodeficiency virus type 1 tat gene in tomato plants and its immunogenic potential in mice.The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.Co-infection with human immunodeficiency virus and tuberculosis in AsiaHeterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.Oral Immunization with a Recombinant Lactococcus lactis-Expressing HIV-1 Antigen on Group A Streptococcus Pilus Induces Strong Mucosal Immunity in the Gut.Vaccine-induced protection from infection of mice by chimeric human immunodeficiency virus type 1, EcoHIV/NL4-3.An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.
P2860
Q21563403-A7B5BA52-159A-4725-8B07-C84F910DEBCEQ24652185-E2F1CBA3-68D7-4544-B62F-8A48D7C9D124Q28472590-828F0315-D88B-41A2-9C71-505A3C66ED7EQ28473841-33391F67-04A3-460A-82DC-4A309C75CB44Q28751663-93B659A8-15E8-41EA-8154-6D6B36B6AA5CQ28972526-A1A1AA68-C22C-498C-92D2-3E5BC5EA0CD4Q30355260-38C06815-CE78-4335-A073-05EFA833FCA4Q30381447-422F17E7-18BD-4FB7-AE4D-72192149C55AQ33323199-959F0CF8-1509-488A-87C1-D496B7CE9217Q33504607-07692802-D00D-4BC8-B295-CD0AFF854C39Q33611719-C6DCA27E-7E56-4B4E-A8D5-367DC8244FD8Q33627537-2E5433E0-0FFD-4B85-AA93-F1B9B9ACBE2EQ33631911-21F3D81B-58DF-4F74-9FB5-29720B433DDDQ33712291-4E7D33FA-F9CA-4A8B-A7DC-445648FEBE96Q33819656-4228B66C-DD58-43BE-9672-95871E7A2C49Q33857396-E395D48E-FD57-4DF5-9BD4-25D184687D53Q33966586-DEE0496E-762B-4C32-B0AF-EAE9079E2719Q34007084-D9883FDF-CC39-453F-A4F0-6C32E2F64108Q34009437-55DBE08B-C32E-4C1F-BD4D-3AA6B56F31C9Q34071050-4AF216E5-1BC9-404B-823B-C7C4BD59DB59Q34157802-E7D81E43-FE9D-4597-8462-E6146CF941D5Q34178201-A2155869-8230-4FEB-8296-588D926620D7Q34178341-26AB3E76-4B2E-49AE-B5CC-2BD00F0BA74EQ34423446-942B1C6A-66BA-46CB-B232-33BCE68C61E5Q34459985-8FBD833C-9687-449C-A49C-6615706DE845Q34468210-ACBE658F-386A-4427-B6B9-3D5B2D5CC435Q34692141-A0AE6835-37F5-42EE-8862-9D1008986EAAQ34971570-ABCB29DE-6CC9-40CE-A4AC-F9867B075AE7Q34993838-5A6F8932-49DD-44E7-9C90-61C4BF40D168Q35674731-82E1C456-FB35-4B70-9916-5909EF55CD13Q35760486-D5DC8606-FAB5-4407-8B3E-B6E7FE448814Q35766088-067E51EA-85CB-4CF0-AE66-3E5FEA469028Q35890514-E83A43AE-6EF8-4EDF-B09B-9A3BE782A91BQ35946931-3AC0542B-A7FB-448F-BE7F-DEAD33995D4BQ36060423-6553D9CA-FA0A-46E5-B5CD-76E9F053B3AFQ36074442-E2A772AC-5DBE-4AFD-85FB-CECC10CADDB1Q36162593-E4F1CE29-B846-425E-A808-99A24FE5D21DQ36260414-521C331D-7EB6-422D-B66F-79D9FBE5A5FBQ36416594-104C679C-A092-4621-ACF2-A17310A9FBAAQ36446900-FEA9141E-8CB8-4111-B2E5-36411B9595AD
P2860
Progress and obstacles in the development of an AIDS vaccine.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Progress and obstacles in the development of an AIDS vaccine.
@ast
Progress and obstacles in the development of an AIDS vaccine.
@en
type
label
Progress and obstacles in the development of an AIDS vaccine.
@ast
Progress and obstacles in the development of an AIDS vaccine.
@en
prefLabel
Progress and obstacles in the development of an AIDS vaccine.
@ast
Progress and obstacles in the development of an AIDS vaccine.
@en
P2860
P356
P1476
Progress and obstacles in the development of an AIDS vaccine.
@en
P2093
Norman L Letvin
P2860
P304
P356
10.1038/NRI1959
P577
2006-12-01T00:00:00Z